Pharmacogenomics of childhood acute lymphoblastic leukemia

Current Opinion in Molecular Therapeutics

Volumn 3, Issue 6, 2001, Pages 567-578

  Brenner, T L ^a   Pui, C H ^a   Evans, W E ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Acute lymphoblastic leukemia; Pharmacogenetics; Pharmacogenomics; Polymorphism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); 6 MERCAPTOPURINE DERIVATIVE; ANTILEUKEMIC AGENT; AZATHIOPRINE; BCR ABL PROTEIN; CARBAMAZEPINE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOCHROME P450; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; FLUOROURACIL; GLUTATHIONE TRANSFERASE; GYRASE INHIBITOR; IMATINIB; MERCAPTOPURINE; METHOTREXATE; PHENOBARBITAL; PHENYTOIN; THIOPURINE METHYLTRANSFERASE; THYMIDYLATE SYNTHASE; TIOGUANINE; XENOBIOTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLOOD TOXICITY; BRAIN TUMOR; BREAST CANCER; CANCER RECURRENCE; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DRUG DISPOSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; HUMAN; INDIVIDUALIZATION; LEUKEMOGENESIS; MUCOSA INFLAMMATION; PATHOGENESIS; PHARMACOGENOMICS; PROGNOSIS;

ANTINEOPLASTIC AGENTS; CHILD; EPIDEMIOLOGY, MOLECULAR; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROGNOSIS;

EID: 0035669961     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (107)

1. Acute lymphoblastic leukemia
2. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia
3. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
4. Backtracking leukemia to birth: Identification of clonotypic gene fusion sequences in neonatal blood spots
5. Presence of clone-specific antigen receptor gene rearrangements at birth indicates an in utero origin of diverse types of early childhood acute lymphoblastic leukemia
6. Detection of clonotypic IGH and TCR rearrangements in the neonatal blood spots of infants and children with B-cell precursor acute lymphoblastic leukemia
7. Molecular genetics, natural history and the demise of childhood leukaemia
8. Biological and therapeutic aspects of infant leukemia
9. Biology and treatment of infant leukemias
10. Topoisomerase II inhibitor-related acute myeloid leukaemia
11. Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion
12. A lack of a functional NAD(P)H: Quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions
13. Susceptibility to childhood acute lymphoblastic leukemia: Influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms
14. The glutathione S-transferase μ-polymorphism and susceptibility to acute lymphocytic leukemia
15. Genetic polymorphisms of N-acetyltransferases 1 and 2 and gene-gene interaction in the susceptibility to childhood acute lymphoblastic leukemia
16. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia
17. Childhood acute lymphoblastic leukemia - Current status and future perspectives
18. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: A report from the children's cancer group
19. Prognostic classification of pediatric T-ALL using oligonucleotide microarrays
20. Pharmacogenomics: Translating functional genomics into rational therapeutics
21. Pharmacogenetics of cancer therapy: Getting personal
22. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia
23. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity
24. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia
25. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance
26. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia
27. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient
28. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus
29. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine
30. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathiopurine
31. Thiopurine methyltransferase genotype and the toxicity of azathiopurine in Japanese
32. Genetic polymorphism of thiopurine S-methyltransferase: Molecular mechanisms and clinical importance
33. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans
34. Ethnic differences in thiopurine methyltransferase pharmacogenetics: Evidence for allele specificity in Caucasian and Kenyan individuals
35. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF)
36. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: Implications for folate intake recommendations
37. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase
38. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during long-term, low dose methotrexate therapy for rheumatoid arthritis: Implications for cardiovascular disease prevention
39. Pharmacogenetics of methotrexate: Toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism
40. Glutathione transferases and cancer
41. Reduced topoisomerase II and elevated alpha class glutathione S-transferase expression in a multidrug resistant CHO cell line highly cross-resistant to mitomycin C
42. Overexpression of glutathione S-transferase and elevation of thiol pools in a multidrug-resistant human colon cancer cell line
43. Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia
44. Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies
45. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia
46. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: A case-control study
47. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes
48. Seqeunce diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
49. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia
50. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia
51. Vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia
52. Vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia
53. A family of drug transporters: The multidrug resistance-associated proteins
54. MDR1/P-GP expression as a prognostic factor in acute leukemias
55. P-glycoprotein and glutathione S-transferase pi in childhood acute lymphoblastic leukaemia
56. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: Prognostic implications
57. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: Results of a 6-year prospective study
58. Optimal immunocytochemical and flow cytometric detection of P-gp, MRP and LRP in childhood acute lymphoblastic leukemia
59. Correlation of P-glycoprotein expression and function in childhood acute leukemia: A children's cancer group study
60. Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier
61. Human K562 transfectants expressing high levels of reduced folate carrier but exhibiting low transport activity
62. Molecular mechanism of antifolate transport-deficiency in a methotrexate-resistant MOLT-3 human leukemia cell line
63. A single amino acid difference within the folate transporter encoded by the murine RFC-1 gene selectively alters its interaction with folate analogues. Implications for intrinsic antifolate resistance and the transporter within the plasma membrane of tumor cells
64. A mutated murine reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate, and an obligatory anion requirement for transport function
65. A reduced folate carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate
66. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia
67. 2-adrenoceptor and response to albuterol in children with and without a history of wheezing
68. 2-agonist therapy in asthma
69. Effects of genetic polymorphism on ex vivo and in vivo function of β2-adrenoceptors in asthmatic patients
70. 2-adrenergic receptor on albuterol bronchodilator pharmacodynamics
71. Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: Role of sodium status
72. ACE polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients
73. Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease
74. Angiotensin I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension
75. Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure
76. Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired echocardiographic studies
77. Renal hemodynamic changes induced by captopril and angiotensin-converting enzyme gene polymorphism
78. Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy
79. Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene
80. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: Implications for treatment with fluorouracil
81. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival
82. Quantitation of intratumoral thymidylate synthase expression predicts for dissfeminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin
83. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
84. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase
85. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers
86. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil
87. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
88. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
89. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
90. Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
91. Selection and characterization of Bcr-Abl positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
92. Mechanism of resistance to the Abl tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
93. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
94. Clinical resistance to STI-571 cancer therapy caused by Bcr-Abl gene mutation or amplification
95. High incidence of secondary brain tumours after radiotherapy and antimetabolites
96. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: Relation to thiopurine metabolism
97. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia
98. Thioguanine substitution alters DNA cleavage mediated by topoisomerase II
99. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine
100. Resistance to 6-thioguanine in mismatch repairdeficient human cancer cell lines correlates with an increase in induced mutations at the HPRT locus
101. Human RNase H-mediated RNA cleavage from DNA-RNA duplexes is inhibited by 6-deoxythioguanosine incorporation into DNA
102. Association of CYP3A4 genotype with treatment-related leukemia
103. Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H: Quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia
104. Characterization of a polymorphism in NAD(P)H: Quinone oxidoreductase (DT-diaphorase)
105. A polymorphism in NAD(P)H:quinone oxidoreductase (NQO1): Relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity
106. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia